October 8, 2025 — Leads & Copy — GeneDx (Nasdaq: WGS) will present pioneering scientific contributions at the American Society of Human Genetics (ASHG) Annual Meeting.
GeneDx will unveil research findings drawn from GeneDx Infinity™, a dataset of nearly one million exomes and genomes and over seven million phenotypic datapoints. The company will showcase 14 pioneering research studies highlighting advancements in genomic newborn screening, neurodevelopmental disorders, diagnostic technologies, and machine learning applications in genomics.
Throughout the week at ASHG, GeneDx will present data showcasing advances in key areas, including unlocking new discoveries and shortening the diagnostic odyssey with GeneDx Infinity, AI and machine learning approaches uncovering the genetic basis of rare diseases, the genetic causes of autism, delivering earlier diagnoses with genomic newborn screening (gNBS), and clinical validation for long read sequencing.
GeneDx collaborated on platform presentations and posters, including topics such as the GUARDIAN Expanded NBS Study, shared and distinct genetic architectures of autism and neuropsychiatric disorders, the superior diagnostic utility of exome/genome sequencing in hearing loss, and benchmarking long-read variant sensitivity across ONT and PacBio platforms.
Additional CoLab Industry Sessions will cover topics such as redefining the limits of what’s possible with sequencing, HiFi sequencing at scale, and accurate and scalable WGS variant prioritization for phenotype-free newborn screening (NBS) with GEM AI.
GeneDx (Nasdaq: WGS) is the global leader in rare disease diagnosis, transforming the way medicine is practiced by making genomics the starting point for health.
Contact:
No contact information provided in press release.
Source: GeneDx
